https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42216 Wed 22 Mar 2023 15:44:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53695 Wed 10 Jan 2024 10:42:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51109 Tue 22 Aug 2023 12:34:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44768 Tue 21 Mar 2023 16:48:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47378 Thu 06 Jul 2023 13:38:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12766 =15 eosinophils per high power field and associated symptoms were present. Age-adjusted and sex-adjusted standardized incidence ratios (SIR) with corresponding 95% confidence intervals (CI) were calculated in comparison to published US population-derived incidence data. EoE was diagnosed in 4 children and 10 adults. EoE is more common compared with the general population; SIR for children was 35.6 (95% CI, 9.3-79.0) and for adults 13.1 (95% CI, 6.2-22.5). Overall, the age-adjusted and sex-adjusted SIR was 16.0 (95% CI, 8.7-25.5). The incidence of EoE in our cohort of patients with CD was increased compared with the general population. Coexistent EoE should be considered in patients with CD who have persistent esophageal symptoms.]]> Sat 24 Mar 2018 08:18:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12769 Sat 24 Mar 2018 08:18:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12380 Sat 24 Mar 2018 08:18:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12433 Sat 24 Mar 2018 08:15:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19968 Sat 24 Mar 2018 07:58:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26864 4 aeroallergens in 47 % (33/70) and reactions to any food allergen in 63 % (50/80) of patients. There was no evidence of monthly concentration of symptomatic esophageal eosinophilia diagnosis in the subgroups of patients with any positive aeroallergen, >4 positive aeroallergens, or history of atopy. The diagnosis of symptomatic esophageal eosinophilia is not made more frequently in the summer months.]]> Sat 24 Mar 2018 07:41:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28359 in vivo in the absence of allergen. Post hoc analysis of gene array data demonstrated significant upregulation of TRAIL and MID1 in a cohort of children with EoE compared with that seen in controls. Conclusion TRAIL regulates MID1 and TSLP, inflammation, fibrosis, smooth muscle hypertrophy, and expression of inflammatory effector chemokines and cytokines in experimental EoE.]]> Sat 24 Mar 2018 07:25:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29786 Tnfsf10^−/−) mice were administered subcutaneous ovalbumin (OVA) followed by oral OVA challenges. In separate experiments, OVA-challenged mice were intraperitoneally administered salmeterol or dexamethasone. Esophageal biopsies from children with EoE revealed increased levels of TRAIL and MID-1 and reduced PP2A activation compared with controls. Tnfsf10^−/− mice were largely protected from esophageal fibrosis, eosinophilic inflammation, and the upregulation of TSLP, IL-5, IL-13, and CCL11 when compared with wild-type mice. Salmeterol administration to wild-type mice with experimental EoE restored PP2A activity and also prevented esophageal eosinophilia, inflammatory cytokine expression, and remodeling, which was comparable to the treatment effect of dexamethasone. TRAIL and PP2A regulate inflammation and fibrosis in experimental EoE, which can be therapeutically modulated by salmeterol.]]> Sat 24 Mar 2018 07:23:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24892 Sat 24 Mar 2018 07:14:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53577 Fri 08 Dec 2023 15:38:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24090 Aspergillus fumigatus allergen mouse model of EoE. Because IL-33 induction was transient in this model and chronicity of IL-33 expression has been demonstrated in humans, naive mice were treated with recombinant IL-33 for 1 wk and esophageal pathology was evaluated. IL-33 application produced changes consistent with phenotypically early EoE, including transmural eosinophilia, mucosal hyperproliferation, and upregulation of eosinophilic genes and chemokines. Th2 cytokines, including IL-13, along with innate lymphoid cell group 2, Th1/17, and M2 macrophage marker genes, were increased after IL-33 application. IL-33-induced eosinophilia was ablated in IL-13 null mice. In addition, IL-33 induced a profound inhibition of the regulatory T cell gene signature. We conclude that IL-33 gene expression is associated with pediatric EoE development and that application of recombinant protein in mice phenocopies the early clinical phase of the human disease in an IL-13-dependent manner. IL-33 inhibition of esophageal regulatory T cell function may induce loss of antigenic tolerance, thereby providing a mechanistic rationale for EoE development.]]> Fri 03 Dec 2021 10:32:37 AEDT ]]>